Ibrahim Aa

Language: Spanish
References: 20
Page: 497-501
PDF size: 398.10 Kb.

ABSTRACT

Raynaud’s phenomenon is characterized by episodes of digital ischemia due to vasospasm recurrence, vascular and neural changes triggered by cold, stress and recurrent trauma. It is classified into primary and secondary. Also, it is more likely to occur in women at an early age and that live in geographical areas with cold weather. Its clinical presentation may be mild to severe; depending on the severity, the treatment will be prompted conservative, medical or surgical.

REFERENCES

1. Araujo A, Gómez N, Aparicio J. Síndrome de Raynaud. MEDUNAB. Vol 5. N°13. 2002. 1-9

2. Bakst R. et al. Raynaud´s Phenomenon: Pathogenesis and Management. J AM ACAD Dermatol. 2008. Vol 59 N°4 pg 633-6533

3. Block J, Sequeira W. Raynaud´s Phenomenon. The Lancet. Vol. 357. June, 2001. 2042-20484

4. Brand FN, Larson MG, Kannel WB. The occurrence of Raynaud’s phenomenon in a general population: the Framingham Study. Vasc Med. 1997 Nov;2(4):296-301.5

5. Cooke J, Marshall J. Mechanisms of Raynaud’s disease. Vascular Medicine 2005; 10: 293–3076

6. Dziadzio M et al. Losartan therapy for Raynaud’s phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 1999; 42(12): 2 6 4 6 - 5 5 .

7. Fredrick M, Wigley M D. Raynaud’s phenomenon. N Engl J Med. 2002; 347:1001-1008

8. Gayraud M. Raynaud’s phenomenon. Joint Bone Spine 74 (2007) e1ee8

9. Hettema M, et al. Bosentan therapy for patients with severe Raynaud’s phenomenon in systemic sclerosis. Ann Rheum Dis 2007 66: 1398-1399

10. Hummers L, et al. Management of Raynaud’s phenomenon and digital ischemic lesions in scleroderma. Rheum Dis Clin N Am 29 (2003) 293–313

11. Joven B, Carreira P. Síndrome de Raynaud: Etiología y Manejo. Reumatol Clin. 2008; 4(2):59-66

12. LeRoy EC, Medsger TA. Raynaud’s phenomenon: A proposal for classification. Clin Exp Rheumatol 10:485, 1992 .PMID: 1458701]

13. Milio G, Corrado E, Genova C. Iloprost treatment in patients with Raynaud’s phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol. Rheumatology 2006;45:999–1004

14. Olsen N, Neilsen SL. Prevalence of primary Raynaud’s phenomenon in young females. Scand J Clin Lab Invest. 1978;37:761-4.

15. Parodi R, Galant F, Greca A. El fenómeno de Raynaud. Anuario Fundación Dr. J. R. Villavicencio. 2007. N° XV. 190-194.

16. Pope J, et al. Prazosin for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 2000;2:CD000956.

17. Sunderkotter C, Riemekasten G. Patho-physiology and clinical consequences of Raynaud’s phenomenon related to systemic sclerosis. Rheumatology 2006;45:iii33–iii35

18. 18.Tan FK, Arnett FC. Genetics factors in the etiology of systemic sclerosis and Raynaud’s phenomenon. Curr Opin Rheumatol. 2000;12:511-9.

19. 19.Thompson AE, et al. Calciumchannel blockers for Raynaud’s phenomenon in systemic sclerosis. Arthritis Rheum 2001;44:1841–7.

20. Wigley FM. Raynaud’s phenomenon. Curr Opin Rheumatol. 1993;5:773-84.